Showing results (171-180 of 530) with videos related to

Sort By:
Pageof 53
Circulation|October 15, 2008
Impact of statin use on outcomes after coronary artery bypass graft surgeryAlexander Kulik, M Alan Brookhart, Raisa Levin, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|August 23, 2005
Identification of individuals with CKD from Medicare claims data: a validation studyWolfgang C Winkelmayer, Sebastian Schneeweiss, Helen Mogun, et al.
Arthritis and Rheumatism|August 20, 2010
Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseasesLaura R Rekedal, Elena Massarotti, Rajesh Garg, et al.
Circulation|April 21, 2004
Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adultsDaniel H Solomon, Sebastian Schneeweiss, Robert J Glynn, et al.
Arthritis and Rheumatism|February 8, 2006
Prescription opioid use among older adults with arthritis or low back painDaniel H Solomon, Jerry Avorn, Philip S Wang, et al.
Epidemiology (Cambridge, Mass.)|January 26, 2016
Tumor Necrosis Factor-α Inhibitor Use and the Risk of Incident Hypertension in Patients with Rheumatoid ArthritisRishi J Desai, Daniel H Solomon, Sebastian Schneeweiss, et al.
JAMA Internal Medicine|December 2, 2014
Statin therapy and risk of fracture: results from the JUPITER randomized clinical trialJessica M Peña, Sara Aspberg, Jean MacFadyen, et al.
Arthritis Research & Therapy|June 15, 2017
Drug safety analyses in a rheumatoid arthritis registry: application of different approaches regarding timing of exposure and confounder measurementDaniel H Solomon, Nancy A Shadick, Michael E Weinblatt, et al.
Annals of the Rheumatic Diseases|June 13, 2014
Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort studySeoyoung C Kim, Sebastian Schneeweiss, Robert J Glynn, et al.
Pharmacoepidemiology and Drug Safety|September 21, 2022
Examining the potential direct cardiovascular benefit of tumor-necrosis factor inhibitor in rheumatoid arthritis: Natural and controlled direct effect analysesKazuki Yoshida, Leslie R Harrold, Nicole Middaugh, et al.
Pageof 53